Kintara Therapeutics, Inc. (KTRA) oversold on the daily! Based on support and resistance we have: Price target: 2.60usd Stop loss: 0.58usd
$KTRA price is holding on strong support. Waiting to see for a bounce
Short term MAs are crossing the longer term MAs and the MACD is rising. I like yesterday's candle retesting the 0 fib level m testing the .38 level and closing above the .23 fib level. Looking for a break of 1.76 to enter for a swing trade. target: 1.92 in the short term.
100m shelf popped out of the blue, now in effect. Phase two data is due and looks to be positive. Cap is under 60m. Seems very undervalued here. The shelf is strange because the CEO has stated that they had enough cash to get through Q4/21, so why the offering now?
Broke out of a trend line and retested 1.30, looks to be heading towards 1.80 based on the sideways pattern. If it breaks out of sideways pattern there may be more upside. Stop loss can be somewhere below the sideways pattern. Kintara will be presenting in H.C. Wainwright Bioconnect 2021 Virtual Conference on January 11 – January 14, 2021. I am expecting them to...
Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.